Results 111 to 120 of about 37,264 (269)

The human heart beta-adrenergic receptors. II. Coupling of beta 2-adrenergic receptors with the adenylate cyclase system.

open access: yes, 1983
The beta-adrenergic stimulation of adenylate cyclase in membranes from human auricles, ventricles, and fetal heart was compared with the binding properties of beta-adrenergic receptors in human auricles.
De Smet, Jean-Marie   +9 more
core  

Exocrine Gland Dysfunction in Parkinson's Disease: Pathophysiology, Clinical Manifestations, and Therapeutic Perspectives—A Narrative Review

open access: yesMovement Disorders Clinical Practice, EarlyView.
Abstract Background Non‐motor symptoms, especially autonomic dysfunction, are major contributors to disability and decreased quality of life in Parkinson's disease (PD). Despite being common and having a wide range of clinical facets, exocrine gland dysfunction is still not well recognized and managed.
Renato P. Munhoz   +2 more
wiley   +1 more source

Decatecholaminization and calcium sensitizers in critically ill patients

open access: yesResearch in Cardiovascular Medicine, 2014
Samad E J Golzari, Ata Mahmoodpoor
doaj   +1 more source

beta-Adrenergic receptors in the developing rabbit lung

open access: yes, 1981
beta-Adrenergic receptors and catecholamine-sensitive adenylate cyclase were identified and partially characterized in membrane fractions of rabbit lungs from day 25 of gestation to adulthood with the beta-adrenergic antagonists (--)-[3H ...
J. A. Whitsett   +4 more
core   +1 more source

Musculoskeletal Outcomes of Glucagon‐Like Peptide‐1 Receptor Agonists Versus Other Antiobesity Agents in Nondiabetic Adults

open access: yesObesity, EarlyView.
ABSTRACT Objective This study aimed to evaluate the association of glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) with risks of osteoporosis, major osteoporotic fractures, and degenerative musculoskeletal disorders in nondiabetic adults with obesity compared with other obesity medications.
Jie‐Syuan Wu   +5 more
wiley   +1 more source

Chiral 2-(3'-(5'-p-chlorophenyl)isoxazolidinyl)ethanolamines as conformationally restrained analogs of methyloxyiminomethyl (MOIM) beta-adrenergic antagonists: Synthesis, configuration and beta-adrenergic properties

open access: yes, 1996
The chiral N-isopropyl- and N-t-butyl-substituted 2-(3'-(5'-p-chlorophenyl)isoxazolidinyl) ethanolamines 2, 3, which can be viewed as conformationally restrained analogs of the corresponding methyloxyiminomethyl (MOIM) beta-adrenergic antagonists 1, were
BRESCHI, MARIA CRISTINA   +11 more
core   +1 more source

Targeting fibrosis in the treatment of lower urinary tract dysfunction

open access: yesThe Journal of Pathology, EarlyView.
Abstract Benign prostatic hyperplasia (BPH) is a widely prevalent age‐associated disease that is the main contributor to lower urinary tract dysfunction (LUTD) in aging men. Although prostate fibrosis has been recognized as a contributor to BPH pathophysiology, there are not any clinically available therapeutics that target this aspect of disease ...
Ajinkya R Limkar   +6 more
wiley   +1 more source

Amplification of cyclic AMP generation reveals agonistic effects of certain beta-adrenergic antagonists

open access: yes, 1990
Some beta-adrenergic receptor (beta AR) antagonists, in addition to blocking receptor-mediated responses, possess agonistic properties or intrinsic sympathomimetic activity (ISA).
Michel, M. C.   +2 more
core  

Blubber Thickening Driven by UCP1 Inactivation: Insights from a Cetacean‐Like Transgenic Mouse Model

open access: yesIntegrative Zoology, EarlyView.
UCP1 inactivation of cetaceans in mice drives BAT whitening and iWAT hyperplasia, promoting fat accumulation for aquatic adaptation. Abstract Cetaceans possess thick blubber, a specialized adipose tissue essential for thermal insulation, a streamlined body form, energy storage, and buoyancy. However, the mechanisms that underpin this adaptation are not
Qian Zhang   +5 more
wiley   +1 more source

Systemic phenoxybenzamine but not beta-adrenergic antagonists block noradrenergic inhibition of cerebellar Purkinje and hippocampal pyramidal neurons

open access: yes, 1988
Previous pharmacological characterization of central noradrenergic receptors has been interpreted as favoring beta-type receptors on cerebellar Purkinje neurons and hippocampal pyramidal neurons.
Bloom, FE   +4 more
core   +1 more source

Home - About - Disclaimer - Privacy